Citations

Clear

85 citation(s) found for "Akhtar, M A B".

Global Burden of Elevated LDL-C
Collaborators, GBD 2023 LDL Cholesterol, Razo, Christian, DeCleene, Nicole K., Johnson, Catherine O., Stark, Benjamin, LeGrand, Kate, Aalruz, Hasan, Abaraogu, Ukachukwu O., Abdelnabi, Mahmoud, Abd-Elsalam, Sherief, Abdelwahab, Siddig Ibrahim, Abdollahi, Arash, Abdrabou, Mostafa M., Abdul‐Rahman, Toufik , Getahun, Habtamu Abebe, Abiodun, Olumide, Abohashem, Shady, Abonie, Ulric Sena , Abourashed, Nagah M , Abramov, Dmitry, Abrar, Mohammed Mehdi, Farha, Rana Kamal Abu, Abubakar, Bilyaminu, Aburuz, Salahdein, Abushanab, Dina, Adams, Lisa C., Adamu, Nuhu Lawan Lawan, Adegbile, Oluwatobi E , Adegoke, Nurudeen A., Adekola, Saheed Ayodeji, Adeleke, Olumide Thomas , Adesina, Miracle Ayomikun, Afoakwah, Clifford, Afolabi, Aanuoluwapo Adeyimika, Afrashteh, Fatemeh , Afrifa-Yamoah, Ebenezer, Agyemang‐Duah, Williams , Ahmad, Suhaib, Ahmed, Asma , Ahmed, Gasha Salih, Ahmed, Luai A., Ahmed, Mehrunnisha Sharif, Ahmed, Meqdad Saleh , Ahmed, M. , Ahmed, Mushood, Ahmed, Syed Anees, Ahmed, Zohra, Aiyer, Aishwarya, Ajami, Marjan, Akalanka, Kasuni H.M. , Akhtar, Muhammad Nadeem, Akrami, Ashley E, Akyea, Ralph Kwame, Hasan, Syed Mahfuz Al , Zoubi, Mohammad Ahmmad Mahmoud Al, Alahdab, Fares , Al-Ahmad, Mohammad M. , Alajajian, Stephen , Alajlani, Muaaz , Alalwan, Tariq A., Al-Amri, Issa Sulaiman, Alanzi, Turki M., Alarifi, Abdullah, Al-Azzam, Sayer, Albashtawy, Mohammed, Al-Dewik, Nader, Algahtani, Fahad D., Algammal, Abdelazeem M, Alhalaiqa, Fadwa Naji, Ali, Mohammad Daud , Ali, Mohammed Usman, Ali, Rafat, Ali, Syed Shujait, AL-Iede, Montaha, Alipour, Morteza, Al-Jabi, Samah W., Alkhatib, Mayson H. , Allawi, Raad Hatim , Allemailem, Khaled S. , (6837737), Mohammed Z. Allouh, Almahmeed, Wael, Al-Marwani, Sabah , Almazan, Joseph Uy, Alnaeem, Mohmmad Minwer, Alotaibi, Haifa F. F., Alqahtani, Saleh A, Alqudah, Mohammad , Alqudimat, Mohammad R, Al-Qudimat, Ahmad Rajeh, Alrimawi, Intima , Alrousan, Sahel Majed, Alshahrani, Najim Z., Altaany, Zaid, Altaf, Awais, Althobiani, Malik A., Altwalbeh, Diala, Al-Worafi, Yaser Mohammed, Aly, Hany, Alzoubi, Karem H., Al-Zubairi, Adel S., Amafah, Joy, Mohammadi, Masoud Aman, Amini, Saeed, Amini-Salehi, Ehsan, Ananda, Roshan A., Ancuceanu, Robert, Anil, Abhishek, Anjana, Prapti, Anuoluwa, Boluwatife Stephen, Anvari, Saeid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Appati, Walter, Arafa, Elshaimaa A , Aravkin, Aleksandr Y. , Areda, Demelash, Aregawi, Brhane Berhe, Torre, Jorge Arias de la, Arruda, Gustavo Aires , Asghari-Jafarabadi, Mohammad , Ashraf, Saad , Asare, Bernard Yeboah‐Asiamah , Atac, Omer, Athari, Seyyed Shamsadin, Atorkey, Prince , Aurangzeb, Khursheed, Awan, Usman Ayub , Awol, Kemal Lemnuro Lemnuro, Ayala, Camila Ospina , Ayli, Berrak Itir, Azad, A.K.M., Azzam, Ahmed Y., Babiker, Rasha, Badar, Muhammad, Badran, Alaa Aboelnour, Baghlaf, Khlood K., Balabekova, Marina, Balakrishnan, Senthilkumar , Baltatu, Ovidiu Constantin , Banach, Maciej, Bashir, Muhammad Irfan , Bashir, Shahid, Bashiri, Azadeh, Bastan, Mohammad-Mahdi, Bayat, Mahdis , Behera, Surama Manjari , Belayneh, Melesse, Bello, Abdulrahman Babatunde , Belo, Luís, Bhaskar, Sonu, Bizzozero-Peroni, Bruno, Bogale, Sitotaw Kerie, Bolourinejad, Paria , Bonny, Aimé , Carvajal, Alejandro Botero, Bouaoud, Souad, Britton, Gabrielle, Bustanji, Yasser, Butt, Zahid A., Cao, Yu, Catapano, Alberico L., Cegolon, Luca, Cembranel, Francieli , Chadwick, Joshua , Chau, Lam Duc, Chaudhary, Anis Ahmad, Chen, An-Tian, Chen, Hana, Chen, Haowei , Cheng, Haojin, Cheung, Ka Ching , Chew, Nicholas WS, Chi, Gerald, Cho, William C. S., Chong, Bryan, Chopra, Deepti, Chopra, Shivani , Cicero, Arrigo Francesco Giuseppe, Criqui, Michael H., Cruz-Martins, Natalia, Dahabiyeh, Lina, Khatri, Bishal Dahal , Dalakoti, Mayank, D’Amico, Emanuele, Damtie, Endalamaw Tesfa, Dandona, Lalit , Dandona, Rakhi, D’Anna, Lucio , Danpanichkul, Pojsakorn, Dardas, Latefa Ali , Das, Sayan Kumar, Davletov, Dimash, Dergaa, Ismail, Derseh, Hunegnaw Almaw , Desale, Aragaw Tesfaw, Devanbu, Vinoth Gnana Chellaiyan, Devegowda, Devananda, Dewan, Syed Masudur Rahman, Dhali, Arkadeep , Dhungel, Bibha, Silva, Diana Dias da, Didehvar, Kimia, Ding, Xueting, Do, Thanh Chi, Do, Thao Huynh Phuong, Dohare, Sushil, Dong, Dachuan, D’Oria, Mario, Dorostkar, Fariba, Doshi, Ojas Prakashbhai, Dresse, Menayit Tamrat , Du, Mi, Ebraheim, Lamiaa Labieb Mahmoud, Edeh, Cynthia , Eftekhari, Behrad, Sedeh, Ashkan Eighaei , Ekholuenetale, Michael , Arab, Rabie Adel El , Eldaboush, Ahmed, El-Dahiyat, Faris , Elhoumed, Mohamed, Elmeligy, Omar Abdelsadek Abdou, Elmonem, Mohamed A., Elmoselhi, Adel B., Elnaem, Mohamed Hassan , Eltahawy, Abdelgawad Salah, Etaee, Farshid, Fakhradiyev, Ildar , Fakorede, Sodiq, Farasani, Abdullah , Fareed, Mohammad , Farhana, Aisha, Faris, MoezAlIslam Ezzat Mahmoud, Farsi, Farima , Fatima, Zareen, Fazylov, Timur, Fekadu, Ginenus , Ferreira, Nuno, Fischer, Florian, Fonzo, Marco , Gadanya, Muktar A., Galali, Yaseen, Ganesh, Balasubramanian , Gangachannaiah, Shivaprakash, Gao, Dingwei, Garcia-Azorin, David, Garg, Paarth, Gautam, Rupesh K., Gaye, Bamba , Gebresilassie, Mizan Habtemichael, Gete, Kalab Yigermal , Ghadirian, Fataneh, Ghaffari, Kazem , Ghamkhar, Arin, Gharaibeh, Lobna, Ghasemi, Mohammadreza, Ghimire, Sailaja, Gil, Artyom Urievich, Gilani, Syed Abdullah , Gohari, Kimiya, Gohil, Megha Nishith , Golechha, Mahaveer, Goleij, Pouya , Golmohammadi, Melika , Goyal, Aman, Grada, Ayman, Grover, Ashna , Gu, Long, Gufue, Zenawi Hagos , Guo, Zheng, Gupta, Sapna , Gurgoglione, Filippo Luca, Haghtalab, Arian, Nam, Nguyen Hai, Hailu, Kirubel Tesfaye , Halder, Pritam, Hamdy, Nadia M., Hamidi, Hossein , Hamidi, Samer, Hamoudi, Rifat, Harsini, Sara, Hasnain, Md Saquib , Hassan, Ikrama, Hassan, Nageeb, Hassan, Treska S , Ahmed, Omed Hassan , Hebert, Jeffrey J., Helmy, Yosra A. , Hiraike, Yuta, Holla, Ramesh, Hoseinzadeh, Mehdi, Hostiuc, Mihaela , Hostiuc, Sorin, Hotwani, Priya, Hu, Yifei, Huang, Junjie, Huang, Yu-Song, Hushmandi, Kiavash, Hussein, Dursa, Hussein, Mohammed Asif , Ibrahim, Ismail A., Ibrayeva, Anel, Ikiroma, Adalia , Ikram, Jibran, Ilic, Irena M., Imam, Mohammad Tarique , Imani, Masoud, Imodoye, Sikiru Opeyemi, Imoh, Lucius Chidiebere , Ionescu, Andreea Iuliana, Ionescu, Radu Tudor, Iqhrammullah, Muhammad, Ishaqui, Azfar Athar, Islek, Duygu , ISMAIL, NAHLAH ELKUDSSIAH, Ismoldayev, Yerlan, Iwagami, Masao , Iyer, Mahalaxmi, Izquierdo-Condoy, Juan S.S., Jafari-Khounigh, Ali , Jahanshahi, Ali, Jahrami, Haitham , Jakovljevic, Mihajlo, Jamal, Armaan, Jamali, Navid, Jamaluddin, Jazlan , Jamshidi, Masoud, Jansen, Robin , Jarrahi, Esmaeil , Javaid, Syed Sarmad , Jawaid, Talha, JEBASINGH, FELIX, Jemal, Mohammed, Ji, Zixiang , Jibat, Nathan T., Jin, Wenyi , Jokar, Mohammad, Joseph, Nitin, Raj, Jesu Vijay Sheldon Joseph Michael, Joshi, Krupal, Joshua, Charity Ehimwenma, Jung, Sang-Hyuk, K, Vaishali, Kadir, Dler Hussein , Kahe, Farima, Kalani, Rizwan, Kalra, Sanjay, Kamenova, Saltanat, Kamorudeen, Ramat T., Kamyshnyi, Oleksandr, Kansal, Subham, Kantar, Rami S., Kar, Debasish , Karakasis, Paschalis, Karimi, Aliasghar, Behnagh, Arman Karimi , Karun, Sadanand , Kazemian, Sina, Kesse-Guyot, Emmanuelle, Khaleel, Anas, Khalid, Nauman, Khalid, Sidra, Khalil, Anees Ahmed , Khan, Ajmal, Khan, Md Abdullah Saeed, Khan, Moien AB, Khan, Muhammad Hamza , Khan, Serab, Khan, Sumaiya, Khan, Yusuf S. , Kheirallah, Khalid A, Khoshvaght, Samira, Khosravi, Sepehr, Kim, Hye Jun, Kim, Kwanghyun, Kisa, Adnan, Kishore, Ladli, Kokkorakis, Michail, Kondybayeva, Aida, Krishan, Kewal, Kua, Chong-Han, Kuddus, Mohammed, Kulimbet, Mukhtar , Kulkarni, Vishnutheertha, Kumar, Dewesh , Kumar, Nitesh, Kumar, Sanjay Kirshan, Kunutsor, Setor K., Kurpad, Krishna Prasad , Kusuma, Dian, Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Lajunen, Timo, Lakanova, Balzhan, Lallukka, Tea, Larsson, Anders O., Le, Duc Tin , Le, Thao T. , Le, Thoa, Le, Trang Thi Bich , Ledda, Caterina, Lee, Hayeon, Lee, Sang-woong, Lee, Sergey Vadimovich, Lee, Seung Won, Leivaditis, Vasileios, Lema, Gebretsadik Kiros , Lemma, Dawit Alemu, Lenjisa, Jimma, Lewis, Mitchelle Shilpa , Li, Chengfeng , Li, Xingang , Li, Yongze, Lim, Lee-Ling, Lindholm, Daniel , Liu, Haipeng , Liu, Xianliang, Liu, Xuefeng, Liu, Yubo, Livingstone, Katherine M., Llanaj, Erand , Lokunarangoda, Niroshan Chandrajith, López-Gil, José Francisco, Lui, Pauline Po Yee, Luo, Peng, Lv, Lei, Lytvyak, Ellina, Ma, Kevin Sheng-Kai, Mabrok, Mahmoud, Machoy-Rakoczy, Monika , Madinehzad, Seyed Ataollah , Maffia, Pasquale, Gomez, Javier A. Magaña, Mahmood, Nozad Hussein, Malik, Md. Zubbair, Malta, Deborah Carvalho, MAMAND, DOSTE RASHID, Maniya, Muhammad Talha, Mansoor, Farheen, Mansourian, Marjan, Manzoor, Shaista, Marghani, Basma Hamed, Martinez-Piedra, Ramon, Martini, Santi, Martorell, Miquel, März, Winfried, Marzouk, Sammer, Masi, Stefano, Masrouri, Soroush , Maude, Richard J. , Mavrovounis, Georgios, McPhail, Steven M., Mendoza, Walter, Menezes, Ritesh G., Mengistie, Emiru Ayalew, Menon, Tara P., Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege, Metwally, Mohamed M.M., Jonasson, Junmei Miao , Mikrajab, Muhammad Agus Naufal, Minhas, Abdul Mannan Khan, Mirrakhimov, Erkin M., Mitra, Sayan , Mitra, Tridip, Modi, Dhruti, Mohamed, Mona Gamal, Ahmed, Khabab Abbasher Hussien Mohamed, Mohammad, Ameen Mosa , Mohammadi, Saeed, Mohammed, Omer, Mohan, Syam , Molla, Tewodros Shibabaw, Molokhia, Mariam, Moni, Mohammad Ali, Namin, Sara Montazeri , Morovvati, Mahdis, Heris, Reza Mosaddeghi, Motappa, Rohith, Mousavi, Seyed Ahmad , Kiasary, Seyed Mohamad Sadegh Mousavi, Yousefi, Kimia Mozahheb , Mubarik, Sumaira, Munkhsaikhan, Yanjinlkham, Musa, Sani, Mwita, Julius C., Nabipoorashrafi, SeyedAli, Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R., Naik, Hiten, Nainu, Firzan, Nartey, Yvonne , Nassar, Mahmoud, Natto, Zuhair S., Naureen, Zakira, Nawaiseh, Hala Khaled, Nayak, Biswa Prakash, Nayak, Vinod C., Nazari, Mojdeh, Ndakotsu, Andrew , Nega, Amanuel Tebabal , Nega, Mulata H., Negash, Abigia Ashenafi, Negoi, Ionut, Nguyễn, Cao Duy, Nguyen, Cuong Tat , Nguyen, Hau Thi Hien, Nguyen, Nghia Phu , Nguyen, Phat Tuan , Nguyen, Van Thanh, Niazi, Robina Khan, Nomura, Shuhei , Noreen, Mamoona , Nawsherwan, Noubiap, Jean Jacques, Nugen, Fred, Nur, Aqsha, Odediji, Saheed Adeyinka, Ogunmodede, O.S., Ojedoyin, Olusegun Olatunji , Ojo, Oluwafemi Adeleke , Okati-Aliabad, Hassan, Oliveira, Gláucia Maria Moraes, Olorukooba, Abdulhakeem Abayomi, Ong, Qi Chwen, Orru, H, Ortiz, A., Ortiz-Prado, Esteban, Osborne, Augustus, Osei, George Nkrumah , Ostrominski, John W. , Oumer, Abdu, Ouyahia, Amel, Owolabi, Mayowa O., Oyebola, Kolapo, Ozsahin, Ilker, Anand, Mahesh Padukudru, Palicz, Tamás , Panda, Sujogya Kumar , Pandi-Perumal, Seithikurippu R., Panos, Georgios D., Papadimopoulos, Ilias, Parija, Pragyan Paramita , Parikh, Romil R., Pascucci, Eleonora, Pasovic, Maja , Passera, Roberto, Patel, Mitesh, Patel, Niki Rut, Patel, Satyananda, Patil, Ashlesh, Patil, Shankargouda, Patoulias, Dimitrios, Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarcikova, Jarmila, Peprah, Prince, Pereira, Gavin, Pirera, Edoardo , Plotnikov, Evgenii, Poluru, Ramesh, Prasad, Manya, Prashant, Akila, Prates, Elton Junio Sady, Pugliese, Nicola Riccardo, Puvvula, Jagadeesh, Qi, Xiang, Qureshi, Ali, Radhakrishnan, Venkatraman, Raghav, Pankaja, Raghav, Yashpal Singh Raghav, Raghuveer, Pracheth , Rahim, Fakher , Rahim, Hawbash Mohammed-Amin, Rahimi, Sajjad, Rahman, Fryad Majeed, Rahman, M Sajjadur , Rahman, Mohammad Hifz Ur, Rahman, Mosiur, Rajendran, Judah, Rajput, Prashant, Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rao, Asad Gul , Rao, Mithun , Rao, Sowmya J, Rasouli-Saravani, Ashkan, Rath, Shree, Rathi, Isha, Rawaf, David Laith , Rawaf, Salman, Reddy, Murali Mohan Rama Krishna, Rezaei, Mina, Rezaei, Nazila, Rezaeian, Mohsen , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo, Ross, Allen Guy Patrick, Rubeshkumar, Polani, Rwegerera, Godfrey Mutashambara , Saad, Aly M. A., Sabet, Cameron John, Sadarangani, Kabir P., Rafiei, Seyed Kiarash Sadat, Sadeghi, Ehsan, Sadeghi, Erfan, Sadeghi, Masoumeh, Sadek, Bassem, Sadek, Mustafa, Sadr, Hossein, Saeb, Mohammad Reza, Saeed, Umar, Saeedi, Maryam , Safiullah, Muhammad , Sahebkar, Amirhossein, Sajadi, S Mohammad, Saleh, Mohamed A., Salehi, Mahdi , Salimi, Sohrab, Samargandy, Saad, Samy, Abdallah M., Saravanan, Aswini , Sarfo, Jacob Owusu, Sarode, Gargi Sachin, Sarode, Sachin C., Sathian, Brijesh, Far, Mehrdad Savabi, Schlaich, Markus P., Schuermans, Art, Sejben, Anita, Semreen, Mohammad H., Senol, Yigit Can, Sessa, Francesco, Sewor, Christian , Seylani, Allen, Shahrahmani, Fatemeh, Shahwan, Moyad Jamal, Sham, Sunder, Shan, Dan, Sharifan, Amin , Sharma, Kamal, Sharma, Ravi Kumar, Sharma, Ujjawal , Shehzadi, Somia , Shetty, Mahabalesh, Shetty, Pavanchand H, Shi, Fanchao , Shi, Huizhong , Shi, Yongfeng, Shiri, Rahman , Shittu, Aminu, Shiue, Ivy, Shoaib, Ambreen, Shool, Sina, Shorofi, Seyed Afshin, Shuval, Kerem, Sia, Ching-Hui, Silva, Luís Manuel Lopes Rodrigues, Singh, Amit, Singh, Baljinder, Singh, Harmanjit, Singh, Harpreet, Singh, Lucky, Singh, Paramdeep, Singh, Siddharth , Singh, Sunil Kumar, Singh, Surjit, Singh, Vanshika , Sinha, Mukesh Kumar, Skryabin, Valentin Yurievich, Sokhal, Balamrit Singh , Sood, Prashant , Soraneh, Soroush , Sorensen, Reed J D , Srivastav, Prateek , Stanikzai, Muhammad Haroon , Starodubova, Antonina V., Stubbs, Peter, Suhag, Alisha, Sulaiman, Sahabi K., Odidi, Muritala Suleiman, Sulistiyorini, Desy , Sun, Jing , Sun, Zhong, Szarpak, Lukasz, Ty, Sree Sudha, Damavandi, Payam Tabaee, Tabatabaei, Seyyed Mohammad, Tabatabai, Shima, Tagiisuran, Balamurugan, Ali, Eman Taha Osman, Soodejani, Moslem Taheri, Taiba, Jabeen, Tajabadi, Shima, Talic, Stella, Talukder, Ashis, Adugna, Dessalegn Tamiru, Tampa, Mircea, Tan, Jianye, Tanabayeva, Dariga, Tanashat, Mohammad , Tang, Jiahao , Tantisattamo, Ekamol, Tariq, Saba, Temsah, Reem, Teramoto, Masayuki, Tesfamariam, Wegen Beyene , Tewari, Jay , Thakar, Vidhi, Thangavelu, Lakshmi, Tharwat, Ismaeel, Thiruvengadam, Muthu , Thomas, Nikhil Kenny, Ticoalu, Jansje Henny Vera, Tiwari, Krishna, Tleshev, Madi, Tonelli, Marcello, Topór-Mądry, Roman , Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Tran, An Thien, Tran, Thang Huu, Duc, Nguyen Tran Minh , Tricò, Domenico , Tse, Gary, Tseriotis, Vasilis-Spyridon, Tualeka, Abdul Rohim , Tye, Sok Cin , Ullah, Riaz, Umair, Muhammad, Umar, Lawan , Ozsahin, Dilber Uzun, Uzunçıbuk, Hande, Vaithinathan, Asokan Govindaraj , Vakili, Omid , Eynde, Jef Van den, Varghese, Joe, Vellingiri, Balachandar, Verma, Poonam, Villalobos-Daniel, Victor E., Vlassov, Vasily, Wang, Nelson, Wang, Qingzhi, Wang, Wanzhou, Wang, Wei, Wang, Yanzhong, Wang, Zhihua, Wani, Tanveer A.A., Wei, Melissa Y., Weintraub, Robert G., Wibowo, Yohanes Cakrapradipta, Wickramasinghe, Dakshitha Praneeth, Wickramasinghe, Nuwan Darshana, Witts, William Kwame , Wonde, Tewodros Eshete , Wongsin, Utoomporn , Wu, Peng, Xiao, Guangqin, Xie, Wanqing , Xu, Suowen, Xu, Wanqing, Yadav, Vikas , Yahoo, Saba, Yang, Hanwen, Yano, Yuichiro , Yao, Haiqiang , Yarahmadi, Amir, Yin, Dehui , Yismaw, Yazachew Engida, Yon, Dong Keon, Yu, Chuanhua, Yu, Elaine A., Yu, Hairui , Yu, Yong , Yuan, Quan, Zafar, Mubashir , Zaghampour, Manijeh, Zamora, Nelson, Zanghì, Aurora , Zargar, Seema , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Beijian, Zhang, Hanyu, Zhang, Julio Min Fei, Zhang, Yunquan, Zhang, Zhichang, Zhanuzakov, Murat , Zhao, Zhongyi, Zheng, Ming‐Hua , Zhong, Anthony , Zhong, Claire Chenwen, Zhou, Hao, Zhou, Jiayan, Zhou, Xiao-Dong, Zhu, Zhengyang , Zhumagaliuly, Abzal, Zitoun, Osama A. , Zoghi, Ghazal , Zoromba, Mohamed Ali, Zumla, Alimuddin, Zyoud, Sa’ed H., Hay, Simon I., Mokdad, Ali H., Murray, Christopher J. L., Roth, Gregory A., Sun, Zhong , Hay, Simon I , Roever, Leonardo , Krishan, Kewal , Moni, Mohammad Ali , Buendía, Jefferson Antonio , Badar, Muhammad , Wickramasinghe, Nuwan Darshana , Nassar, Mahmoud , Dewan, Syed Masudur Rahman , Naik, Ganesh R. , Wang, Yanzhong , Rath, Shree , Karakasis, Paschalis , Zheng, Ming-Hua , Taiba, Jabeen , Razo, Christian , DeCleene, Nicole K., LeGrand, Kate E , Abaraogu, Ukachukwu Okoroafor , ElHafeez, Samar Abd , Abdelmasseh, Michael , Abdelnabi, Mahmoud , Abd‐Elsalam, Sherief , Elshenawy, Rasha Abdelsalam , Abdelwahab, Siddig İbrahim , Abdolizadeh, Ali , Abdollahi, Arash, Abdoun, Meriem , Abdrabou, Mostafa M. , Abdulah, Deldar Morad , Abdullahi, Auwal , Shenkut, Melese, Abiodun, Olugbenga Olusola , Abiodun, Olumide A , Abohashem, Shady , Abtahi, Dariush , Farha, Rana Kamal Abu , Abubakar, Bilyaminu , Abuhelwa, Ahmad Y. , Abukhadijah, Hana J , Aburuz, Salahdein , Adamu, Nuhu Lawan , Adane, Mesafint Molla , Addo, Isaac Yeboah , Adedokun, Kamoru Ademola , Adekola, Saheed Ayodeji, Adesina, Miracle Ayomikun , Adisu, Molalign Aligaz , Adnan, Mohd , Afoakwah, Clifford , Afolabi, Aanuoluwapo Adeyimika, Afrifa‐Yamoah, Ebenezer , Afzal, Saira , Agordoh, Percival Delali , Ahmad, Aqeel , Ahmad, Khabir , Ahmad, Sajjad , Ahmed, Gasha Salih, Ahmed, Nesredin , Ajami, Marjan , Akhtar, Muhammad Nadeem , Akindele, Mukadas Oyeniran , Akkaif, Mohammed Ahmed , Akyea, Ralph Kwame , Zoubi, Mohammad Ahmmad Mahmoud Al, Alalwan, Tariq A. , Al‐Aly, Ziyad , Al-Amri, Issa Sulaiman , Alanzi, Turki Matar Khalaf, Al-Ashwal, Fahmi Y. , Al‐Azayzih, Ahmad , Al-Azzam, Sayer , Al-Bashaireh, Ahmad M. , ALBashtawy, Mohammed , Aleidi, Shereen M. , Algahtani, Fahad D. , AlHabib, Khalid F. , Ali, Abid , Ali, Asgar , Ali, Bassam R. , Al‐Iede, Montaha , Alif, Sheikh Mohammad , Alipour, Morteza, Al‐Jabi, Samah W. , Aljunid, Syed Mohamed , Alkubati, Sameer Abdulmalik , Almagharbeh, Wesam Taher , Almahmeed, Wael , Almazan, Joseph Uy , Alniss, Hasan Yaser , Alomari, Mahmoud A. , Alotaibi, Haifa F. , Alqahtani, Saleh A. , Alqudimat, Mohammad R. , Al-Qudimat, Ahmad Rajeh , Al‐Raddadi, Rajaa , Alsbou, Mohammed , Alshahrani, Najim Zafer , Al-Shami, Ali Salman , Altaf, Awais , Althobiani, Malik A , Alwafi, Hassan , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Al‐Zalabani, Abdulmohsen H. , Alzoubi, Abdallah , Alzoubi, Karem Hasan , Amafah, Joy, Amin, Amr , Amini, Saeed, Amini‐Salehi, Ehsan , Amusa, Ganiyu , Ang, Song Peng , Anieto, Ebuka Miracle , Anil, Abhishek , Anjana, Dr. Prapti, Anvari, Saeid, Appati, Walter , Arabloo, Jalal , Arafat, Mosab , Areda, Demelash, Arefnezhad, Reza , Torre, Jorge Arias de la, Aripov, Timur , Arockiaraj, Jesu , Asdaq, Syed Mohammed Basheeruddin , Ashraf, Syed Amir , Ashraf, Tahira , Ataç, Ömer , Athar, Mohammad , Athari, Seyyed Shamsadin , Aurangzeb, Khursheed , Awan, Sana Javaid , Awol, Kemal Lemnuro, Awotidebe, Adedapo Wasiu , Aylı, Berrak Itır , Azarboo, Alireza , Aziz, Sadat Abdulla , Azzolino, Domenico , Babu, Abraham Samuel , Babu, Giridhara R. , Badiye, Ashish , Baghlaf, Khlood K , Baig, Atif Amin , Bakhshali, Mohamad Amin , Banach, Maciej , Banik, Palash Chandra , Barqawi, Hiba Jawdat , Barrow, Amadou , Barua, Lingkan , Bashir, Shahid , Bashiri, Azadeh , Bastan, Mohammad‐Mahdi , Bayih, Mulat Tirfie , Beeraka, Narasimha Murthy , Begum, Tahmina , Behera, Priyamadhaba , Behnam, Babak , Ramírez, Diana Fernanda Bejarano , Belo, Luı́s , Berihun, Abiye Assefa , Bhattacharjee, Priyadarshini , Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Biswas, Atanu , Biswas, Bijit , Bizzozero‐Peroni, Bruno , Bodur, Mahmut , Bogale, Sitotaw Kerie , Bohn, Lucimére , Boloor, Archith , Carvajal, Alejandro Botero , Boudalia, Sofiane , Bugiardini, Raffaele , Busch, Felix , Bustanji, Yasser, Campos, Luciana Aparecida , Catapano, Alberico Luigi , Cegolon, Luca , Cenko, Edina , Cerin, Ester , Chakraborty, Chiranjib , Chandika, Rama Mohan , Chandrasekar, Eeshwar K , Chandrasekaran, Baskaran , Chattu, Vijay Kumar , Chaudhary, Anis Ahmad , Chaudhuri, Sirshendu , Cheema, Asad Ali Ahmed , Chichagi, Fatemeh , Ching, Patrick R , Cho, William C.S., Choi, Dong‐Woo , Chong, Bryan , Chopra, Deepti , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chu, Dinh‐Toi , Chukwu, Chidozie Williams , Chung, Sheng‐Chia , Chung, S. Y. , Cicero, Arrigo F.G. , Cosma, Claudia , Criqui, Michael H. , Dadras, Omid , Dai, Xiaochen , Dai, Zhaoli , Dalakoti, Mayank , D’Amico, Emanuele , Tesfa, Endalamaw , Danpanichkul, Pojsakorn , Darcho, Samuel Demissie , Davletov, Dimash , Davletov, Kairat , Dejenie, Tadesse Asmamaw , Bo’, Cristian Del , Delgado‐Enciso, Iván , Denova‐Gutiérrez, Edgar , Dergaa, Ismail , Dervišević, Emina , Devegowda, Devananda , Dewan, Syed Masudur Rahman , Dhimal, Meghnath , Dhungel, Bibha , Do, Thanh Chi, Phuong, Thao Huynh, Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Dourado, Paulo Magno Martins , Dowou, Robert Kokou , Du, Mi , Duncan, Bruce Bartholow , Durães, André Rodrigues , Ebohon, Osamudiamen , Eftekhari, Behrad , Eladl, Mohamed Ahmed , Eldaboush, Ahmed , Elgendy, Islam Y. , Elhadi, Muhammed , El‐Huneidi, Waseem , Elmonem, Mohamed A. , Elmoselhi, Adel B. , Fabin, Natalia , Fadaka, Adewale Oluwaseun , Fagbamigbe, Adeniyi Francis , Fakorede, Sodiq , Fatima, Zareen , Fayaz, Mohammad , Fazylov, Timur, Fernández‐Jiménez, Rodrigo , Fischer, Florian, Fogacci, Federica , Foschi, Matteo , Gadanya, Muktar A., Gajdács, Márió , Galali, Yaseen , Ganesan, Balasankar , Gangachannaiah, Shivaprakash , Gašević, Danijela , Habtemichael, Mizan , Getacher, Lemma , Jolfayi, Amir Ghaffari , Ghamkhar, Arin, Ghazy, Ramy Mohamed , Ghimire, Sailaja, Ghith, Nermin , Gil, Artyom , Gill, Paramjit Singh , Gnedovskaya, Elena V. , Goh, Lay Hoon , Gohari, Kimiya, Golechha, Mahaveer , Goulart, Alessandra C. , Goyal, Aman , Grada, Ayman , Gu, Long , Gubari, Mohammed Ibrahim Mohialdeen , Guha, Avirup , Gunawardane, Damitha Asanga , Gupta, Rajeev , Gurgoglione, Filippo Luca , Guzmán-Esquivel, José , Guzmán-Muñoz, Eduardo , Haghtalab, Arian , Halder, Pritam , Hamdy, Nadia Μ. , Hammad, Eman A. , Hanif, Asif , Hanifi, Nasrin , Hankey, Graeme J. , Harsini, Sara , Hartmann, Phillipp , Hasan, Ikramul , Hashempur, Mohammad Hashem , Hassan, Amr , Hassan, Ibrahim Nagmeldin , Hayat, Khezar , Hezam, Kamal , Hiraike, Yuta , Holla, Ramesh , Hostiuc, Sorin , Htay, Mila Nu Nu , Huang, Junjie, Hushmandi, Kiavash , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ibrahim, Khalid S. , Ibrayeva, Anel , Ikram, Jibran, Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Imodoye, Sikiru O. , Inbaraj, Leeberk Raja , Ionescu, Radu Tudor, Iqhrammullah, Muhammad , Irham, Lalu Muhammad , Ishaqui, Azfar Athar , Ismail, Nahlah Elkudssiah , Ismoldayev, Yerlan, Isola, Gaetano , Izquierdo‐Condoy, Juan S. , Jacob, Jaison , Jahanshahi, Ali , Jamal, Armaan , Jamali, Navid , James, Jerin , Jamshidi, Masoud , Jawaid, Talha, Jayasinghe, Yovanthi Anurangi , Jemal, Mohammed , Jeong, Seogsong , Jeswani, Bijay Mukesh , Jibat, Nathan Tolemariam , Jokar, Mohammad , Joó, Tamás , Joseph, Akaninyene Paul , Joseph, Mickaël Antoine , Joseph, Nitin , Joshi, Krupal , Jürisson, Mikk , K, Vaishali , Kakkar, Ashish Kumar , Kalani, Rizwan , Kalavani, Khalil , Kalra, Sanjay , Kamorudeen, Ramat T. , Kamyshnyi, Oleksandr , Kanaan, Saddam Fuad , Kanmodi, Kehinde Kazeem , Kantar, Rami S. , Kapoor, Neeti , Karajizadeh, Mehrdad , Karakasis, Paschalis , Karasneh, Reema A. , Kashoo, Faizan , Kashyap, Manoj Kumar , Kausar, Mohd Adnan , Kazemian, Sina , Kebede, Yabets Tesfaye , Kesse‐Guyot, Emmanuelle , Khademi, Reza , Khader, Yousef , Khajuria, Himanshu , Khaleel, Anas , Khalid, Sidra , Khalili, Anita , Khalili, Pantea , Khan, Maseer , Khan, Mohammad Idreesh , Khasbage, Sameer Uttamaro , Khatatbeh, Moawiah Mohammad , Khosla, Pavan , Khosravi, Sepehr , Kimokoti, Ruth W , Kısa, Adnan , Kishore, Ladli , Kivimäki, Mika , Kokkorakis, Michail , Kolahi, Ali‐Asghar , Kompani, Farzad , Kondybayeva, Аida , Korzh, Oleksii , Kostev, Karel , Laxminarayana, Sindhura Lakshmi Koulmane , Kua, Chong-Han , Kuddus, Mohammed , Kumar, Chandan , Kumar, G Anil , Kumar, Jogender , Kumar, Laksh , Kundu, Amartya , Kundu, Satyajit , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kytö, Ville , Lahariya, Chandrakant , Lakanova, Balzhan, Lantos, Tamás , Larebo, Yilma Markos , Lasrado, Savita , Lee�, HwaMin , Lee, Wei‐Chen , Leivaditis, Vasileios , Lenjisa, Jimma Likisa , Li, Ming‐Chieh , Li, Qiang , Li, Shaojie , Lim, Lee-Ling , Lodhi, Madeeha Shahzad , Lokunarangoda, Niroshan Chandrajith , López-Gil, José Francisco , Lorkowski, Stefan , Lucchetti, Giancarlo , Lui, Pauline Po Yee , Lv, Lei , Lytvyak, Ellina , Amin, Hawraz Ibrahim M. , Maffia, Pasquale , Magaña‐Gómez, Javier A. , Mahalleh, Mehrdad , Malik, Ahmad Azam , Malik, Tabarak , Malta, Déborah Carvalho , Mamand, Doste R. , Maniya, Muhammad Talha , Mannethodi, Kamaruddeen , Mansoor, Farheen, Mansourian, Marjan , Maqsood, Kaleem , Marateb, Hamid Reza , Marghani, Basma H. , Marino, Mirko , Martínez, Ramón , Martini, Daniela , Martini, Santi , Martorell, Miquel , März, Winfried , Marzouk, Sammer , Masi, Stefano , Mathur, Neeta , Matozinhos, Fernanda Penido , Mattiello, Rita , Mavrovounis, Georgios , McPhail, Steven , Mehto, Subhash , Meles, Hadush Negash , Menezes, Godfred Antony , Menon, Tara Pattilachan, Mensah, George A. , Merlino, Giovanni , Meštrović, Tomislav , Mettananda, Chamila Dinushi Kukulege , Mettananda, Sachith , Metwally, Mohamed M M, Mikrajab, Muhammad Agus, Minhas, Abdul Mannan Khan , Mittal, Madhukar , Mohamed, Nouh Saad , Ahmed, Khabab Abbasher Hussien Mohamed , Mohammad, Taj , Mohammadi, Abbas , Mohammadi, Mokhtar , Mohammadian-Hafshejani, Abdollah , Mohsen, Yazan , Shibabaw, Tewodros , Molokhia, Mariam , Monazzami, Amirabbas , Ghalibaf, AmirAli Moodi , Morovvati, Mahdis, Motappa, Rohith , Mozafar, Mehrdad , Mubarik, Sumaira , Muhammad, Jibran Sualeh , Munkhsaikhan, Yanjinlkham, Munshi, Anjana , Musa, Sani , Muthu, Sathish , Mwita, Julius Chacha , Myung, Woojae , Nainu, Firzan , Nargus, Shumaila , Nasrollahizadeh, Amir , Nassar, Mahmoud, Nauman, Javaid , Navaratna, Samidi Nirasha Kumari , Nawaiseh, Hala K. , Nayak, Biswa Prakash, Nega, Mulata Haile , Negash, Abigia Ashenafi , Negoi, Ionuţ , Abadi, Reza Nejad Shahrokh , Nematollahi, Mohammad Hadi , Nieddu, Luciano , Nketia, Richmond , Noubiap, Jean Jacques , Nri-Ezedi, Chisom Adaobi , Ntsekhe, Mpiko , Nugen, Fred , Oancea, Bogdan , Odat, Ramez M. , Oddi, Fabio Massimo , Oh, In‐Hwan , Okekunle, Akinkunmi Paul , Okonji, Osaretin Christabel , Olorukooba, Abdulhakeem Abayomi , Ong, Qi Chwen , Ordak, Michał , Orscelik, Atakan , Ortiz‐Prado, Esteban , Osuagwu, Uchechukwu Levi , Oumer, Abdu , Ouyahia, Amel , Özşahin, İlker , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Georgios D. , Papa, Mario Virgilio , Pardhan, Shahina , Passera, Roberto , Patel, Kunal Nitinkumar , Patel, Neel Navinkumar , Patel, Satyananda, Patil, Shankargouda, Patoulias, Dimitrios , Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarčíková, Jarmila , Peprah, Prince , Pereira, Gavin, Perico, Norberto , Perna, Simone , Petermann‐Rocha, Fanny , Pirnejad, Habibollah , Plotnikov, Evgenii, Poddighe, Dimitri , Poluru, Ramesh , Porntaveetus, Thantrira , Pradhan, Pranil Man Singh , Prasad, Manya , Prashant, Akila , Pugliese, Nicola Riccardo , Puvvula, Jagadeesh , Qiu, Jia-Yong , Radhakrishnan, Venkatraman, Raghav, Pankaja Raghav, Rahamon, Sheu Kadiri , Rahim, Hawbash Mohammed-Amin , Rahimi, Sajjad , Rahman, Muhammad Aziz , Raj, Jeffrey Pradeep , Raja, Adarsh , Rajendran, Judah , Rajput, Prashant , Ramadan, Mahmoud M. , Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rashedi, Vahid , Rasouli‐Saravani, Ashkan , Rath, Shree , Rathi, Isha , Rathish, Devarajan , Rauniyar, Santosh Kumar , Rawassizadeh, Reza , Ray, Asit , Redwan, Elrashdy M , Rehman, Najeeb Ur , Remuzzi, Giuseppe , Rezaei, Nazila , Romadlon, Debby Syahru , Romoli, Michele , Rony, Moustaq Karim Khan , Ross, Allen Guy , Roy, Sharmistha , Roy, Shubhanjali , Russo, Michele , Saber-Ayad, Maha Mohamed , Sabet, Cameron John , Sadarangani, Kabir P. , Rafiei, Seyed Kiarash Sadat , Saddique, Muhammad Nabeel , Sadee, Bashdar Abuzed , Sadeghi, Masoumeh , Sadek, Bassem Shaban , Sadr, Hossein, Saeb, Mohammad Reza , Saeed, Mοhd , Saeedi, Maryam , Saghazadeh, Amene , Sagoe, Dominic , Sah, Ashok Kumar , Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajadi, S. Mohammad, Sajid, Mirza Rizwan , Saki, Morteza , Sakshaug, Joseph W. , Salami, Afeez Abolarinwa , Saleem, Rahman Shah Zaib , Salihu, Abubakar Tijjani , Salimi, Sohrab , Samargandy, Saad J. , Samodra, Yoseph Leonardo , Samy, Abdallah M., Sarfo, Jacob Owusu , Sarmadi, Mohammad , Sarode, Gargi Sachin , Sassano, Michele , Sathian, Brijesh , Narayanan, Mukesh Kumar Sathya , Schlaich, Markus P. , Schuermans, Art , Schwarz, Ghil , Sejben, Anita , Selvaraj, Siddharthan , Semreen, Mohammad H. , Şenol, Yiğit Can , Şerban, Dragoş , Sethi, Yashendra , Setiawan, Christianus Heru , Shahid, Samiah , Shahini, Endrit , Shahrahmani, Fatemeh, Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shan, Dan, Shanawaz, Mohd , Shannawaz, Mohammed , Sharif, Nadim , Sharma, Bhoopesh Kumar , Sharma, Bunty, Sharma, Manoj , Sharma, Vishal , Shastry, Shamee , Sheidaei, Ali , Shenoy, Rekha R. , Shimels, Tariku , Shittu, Aminu , Shoaib, Ambreen , Shool, Sina , Shrestha, Sunil , Shuval, Kerem , Sia, Ching‐Hui , Siddig, Emmanuel Edwar , Siddiqi, Ahmed Kamal , Siddiqua, Ayesha , Silva, Diego Augusto Santos , Simkhada, Padam Prasad , Singh, Amit Kumar, Singh, Baljinder, Singh, Harpreet, Singh, Jasvinder A. , Singh, Lucky, Singh, Poornima Suryanath , Singh, Puneetpal , Sinha, Mukesh Kumar , Sinha, Ratnesh , Skryabin, Valentin Yurievich , Sorrentino, Michele , Spartalis, Michael , Stachteas, Panagiotis , Владимировна, Стародубова Антонина, Straube, Sebastian , Stubbs, Peter W. , Su, Chen‐Yang , Subramaniyan, Vetriselvan , Suhag, Alisha , Sulaieva, Oksana , Sun, Jing , Swain, Chandan Kumar , Szarpak, Łukasz , Y, Sree Sudha T, Damavandi, Payam Tabaee , Tabarés‐Seisdedos, Rafael , Tabatabaeizadeh, Seyed‐Amir , Tabche, Celine , Tadele, Afework , Ali, Eman T. , Soodejani, Moslem Taheri , Tajabadi, Shima, Talic, Stella , Talukder, Ashis , Zadeh, Seyed Saeed Tamehri , Tampa, Mircea Ştefan , Tantisattamo, Ekamol , Tariku, Mengistie Kassahun , Tavangar, Seyed Mohammad , Tedla, Mebrahtu G. , Teramoto, Masayuki , Tesfu, Azimeraw Arega , Tharwat, Ismaeel, Tharwat, Samar , Thienemann, Friedrich , Tiruye, Tenaw Yimer , Tleshev, Madi, Tomo, Sojit , Tonelli, Marcello , Touvier, Mathilde , Tran, An Thien, Tran, Thang Huu, Tristan, Christopher Daniel , Tse, Gary , Tseriotis, Vasilis‐Spyridon , Udoakang, Aniefiok John , Ullah, Atta , Ullah, Saeed , Umair, Muhammad, Upadhya, Dinesh , Upadhyay, Era , Usman, Jibrin Sammani , Ozsahin, Dilber Uzun , Uzunçıbuk, Hande , Varghese, Joe , Vasankari, Tommi Juhani , Vellingiri, Balachandar , Venketasubramanian, Narayanaswamy , Verma, Akshaya Kumar , Villalobos-Daniel, Victor Eduardo , Wan, Jin‐Yi , Wang, Cong , Wang, Nelson , Wang, Shaopan , Wang, Shu , Wang, Youxin , Wani, Tanveer A. , Waqar, Ahmed Bilal , Weintraub, Robert G, Wibowo, Yohanes Cakrapradipta, Wicaksana, Anggi Lukman , Wickramasinghe, Dakshitha Praneeth , Wilandika, Angga , Xu, Site , Xu, Suowen , Xu, Xiaoyue , Yadegar, Amirhossein , Yahoo, Saba, Yamagishi, Kazumasa , Yaribeygi, Habib , Yesuf, Subah Abderehim , Yon, Dong Keon , Yonemoto, Naohiro , Yuan, Quan, Yuzbashian, Emad , Zamagni, Giulia , Zawiah, Mohammed , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Casper J. P. , Zhong, Claire Chenwen , Zhou, Xiao-Dong, Zhumagaliuly, Abzal , Zoromba, Mohamed Ali , Zumla, Alimuddin I. , Zyoud, Ahed H. , Zyoud, Shaher H. , Mokdad, Ali H. , Murray, Christopher J. L., Roth, Gregory A., Kheirallah, Khalid Ahmed , Saad, Aly M A , Sadeghi, Erfan

Mayo Clinic

JAMA | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.8628 | PMID 42525403 Get It

Importance Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C–related burden is critical for guiding prevention and treatment strategies. Objectives To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends. Design, Setting, and Population This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals. Exposure Population-level LDL-C concentrations. Main Outcomes and Measures Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C–attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals. Results In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C–attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings. Conclusions and Relevance Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.
Real-world evaluation of germline pathogenic variants (PVs) in cancer-predisposition genes among unselected South Asian women with breast or ovarian cancer.
Shilpakar, Ramila , Karki, Aditi, Mina, Syeda A. , Yeakub, Nadia, Acharya, Bibek , Acharya, Sandhya Chapagain , Naseer, Hafsa, Khatun, Nazrina , Akhtar, Parveen , Mukhopadhyay, Asima , Pruthi, Sandhya, Goetz, Matthew P., Couch, Fergus J., Aziz, Zeba , Yadav, Siddhartha , Pramanik, Raja , Kataria, Babita , Pruthi, Sandhya , Bakkum‐Gamez, Jamie N. , Goetz, Matthew P. , Kaufmann, Scott H. , Couch, Fergus J. , Islam, Muhammad Rafiqul

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 10513-10513

10.1200/jco.2026.44.16_suppl.10513 Get It

10513 Background: Prior reports of high frequency of BRCA1 and BRCA2 ( BRCA1/2 ) PVs among South Asian women from Bangladesh, India, Nepal, and Pakistan with breast or ovarian cancer require validation in large prospective unselected cohorts. Methods: Individual-level anonymized patient data from two prospective cohorts were pooled to evaluate the prevalence of germline PVs among South Asian women: the South Asian Regional Alliance for Hereditary Cancers (SARAH Consortium) in Bangladesh, Nepal, and Pakistan, and the previously reported Nurse-led Genetic Counseling and Awareness (NuGenA) expansion cohort in India. Both studies enrolled consecutive cases of histologically confirmed newly diagnosed breast or epithelial ovarian cancer irrespective of age at diagnosis or family history. In both studies, participants completed questionnaires on personal and family history (first-, second- or third-degree) and provided blood for germline genetic testing after written consent. PVs in cancer predisposition genes including ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MSH2, MSH6, PALB2, RAD51C, RAD51D, and TP53 were identified as part of the studies utilizing a multigene panel and the results were returned to ordering clinicians. The data cutoff date for this analysis was November 30, 2025. Results: The analysis included 1,711 South Asian women with breast (n=1,210) or ovarian (n=501) cancer. A family history of breast or ovarian cancer was noted in 177 (10.3%). Among breast cancers, 94% were invasive, 84% were ductal, 35% were triple-negative and over two-thirds presented with nodal involvement. Germline PVs across 13 predisposition genes were observed in 17.7% of breast and 35.9% of ovarian cancers. Notably, BRCA1/2 PVs accounted for most of these PV (13.6% of breast and 28.3% of ovarian cancer cases) with PVs in all genes except BRCA1/2 under 1%. The frequency of BRCA1/2 PVs was 24.4% in triple-negative breast cancer and 8.0% in ER+/HER2-. BRCA1/2 PV carriers were diagnosed with breast cancer at a younger age than non-carriers (Median age: 42 vs 46 years, P<0.001), with no age difference observed in ovarian cancer (50 vs. 51 years, P=0.79). Notably, among the 306 BRCA1/2 PV carriers identified, 229 (74.2%) did not report a family history of breast or ovarian cancer. Conclusions: We confirm a high prevalence of BRCA1/2 PVs among unselected South Asian women with either breast or ovarian cancer. The observations of younger age at cancer diagnosis, and low rates of family history support the need for population-specific germline genetic testing and risk management strategies in South Asia.
Crisis-related self-reported symptoms of posttraumatic stress disorder in graduate medical education trainees: results from a multi-institutional study
Akhtar, Saadia, West, Colin P. , Satele, Daniel , He, Celestine , Thomas, Larissa R. , Sliwka, Diane, Julian, Katherine A. , Leitman, I Michael, Ripp, Jonathan, Satele, Daniel V, West, C P , Akhtar, Saadia R. , Sliwka, Diane, Dyrbye, Liselotte N. , Ripp, Jonathan

Mayo Clinic

Academic Medicine | May 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/acamed/wvag157 | PMID 42179175 Get It

Abstract Purpose Crisis periods—defined as sustained disruptions to the clinical environment resulting in increased workload, exposure to high-acuity patient care, or limited access to coping resources—can lead to posttraumatic stress disorder (PTSD) among residents and fellows (trainees). By examining self-reported pandemic-related PTSD symptoms, associated risk factors, and their consequences, this study aims to identify vulnerable groups and inform institutional strategies to support trainee well-being during and after crisis events. Method A multi-institutional cross-sectional survey was conducted at 3 U.S. academic medical centers between April and May 2022. Measures included the Primary Care PTSD Screen for DSM-5 (range 0 to 5, scores ≥4 indicate probable PTSD), 4-item PROMIS Social Isolation scale (normed T-score range 0 to 100 scale with higher scores indicating greater isolation), items exploring intent to stay at one’s institution, and demographics. Multivariable analysis adjusted for demographics, specialty, and postgraduate year. Results Of 6,057 eligible trainees, 3,185 (53%) participated in the survey, with 3,109 completing the PTSD screening. A total of 190 (6%) trainees screened positive for self-reported PTSD symptoms. Multivariable analysis revealed that female trainees had a higher odds of screening positive for self-reported PTSD symptoms compared to males (odds ratio [OR] 1.45; 95% confidence interval [CI], 1.03-2.04; P = .03). Greater social isolation was independently associated with increased PTSD risk (OR 1.09; 95% CI, 1.07-1.11; P &lt; .001). Additionally, trainees who did not intend to remain at their institution after training were more likely to screen positive for PTSD (OR 1.74; 95% CI, 1.17-2.58; P = .01). Conclusions Female gender, greater social isolation, and reduced intention to remain at one’s institution are independently associated with self-reported PTSD symptoms in trainees. Recognizing these relationships may enable health care leaders to proactively identify trainees at higher risk during crisis periods and to implement targeted, evidence-based interventions that promote well-being and workforce retention.
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
Demographics and mortality trends of hypertensive heart failure in the United States, 2006–2020: Insights from the CDC WONDER database
Haleem, Syed Mohammad , Zaman, Asad , Humayun, Mohammad A, Mubariz, Muhammad , Faisal, Abdul Rafae , Akhtar, Faisal , Laiba, FNU, Maity, Rick , Dhali, Arkadeep , Maity, Rick , Faizan, Muhammad , Singh, Pramod , Humayun, Mohammad Abdullah, Akhtar, Faisal Naveed

Mayo Clinic

Journal of International Medical Research | April 10, 2026 | Volume: 54 | Issue: 4 | Pages: No page available

10.1177/03000605261417063 | PMID 41956996 Get It

Objective To comprehensively examine hypertension- and heart failure–related mortality rates in the United States to develop a targeted approach to health policy development. Methods We analyzed death certificates from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database, focusing on mortality caused by hypertensive heart failure in adults aged ≥25 years from 2006 to 2020. Age-adjusted mortality rates per 1,000,000 and annual percent changes were calculated and categorized by year, sex, race, urban status, age group, and census region. Results A total of 268,545 deaths occurred due to hypertensive heart failure between 2006 and 2020. The overall age-adjusted mortality rates increased from 60.5 in 2006 to 134.9 in 2020. Males had higher age-adjusted mortality rates than women (76.6 vs. 73.8). Older-aged people exhibited significantly higher age-adjusted mortality rates than young and middle-aged adults. Age-adjusted mortality rates were highest in non-Hispanic Blacks/African Americans and lowest in non-Hispanic Asians/Pacific Islanders (126.8–43.6). Furthermore, age-adjusted mortality rates were highest in individuals from nonmetropolitan areas and the Western region. Conclusion Following a period of decline, the age-adjusted mortality rates increased until 2020. The highest age-adjusted mortality rates were observed in non-Hispanic Blacks and nonmetropolitan areas. An urgent restructuring of healthcare policy is needed to reduce heart failure-associated mortality.
Placental ferroptosis and impaired fetal growth in symptomatic and asymptomatic SARS-CoV-2 infections
Cariaco, Yusmaris , Nik-Akhtar, Abolfazl , Brien, Marie‐Eve , Menzies, Keir J. , Girard, Sylvie , Bainbridge, Shannon , Menzies, Keir , Sylvie, Girard

Mayo Clinic

Clinical Science | March 26, 2026 | Volume: 140 | Issue: 5 | Pages: 681-697

10.1042/cs20257407 | PMID 41885260 Get It

Abstract SARS-CoV-2 infection disrupts iron homeostasis in organs such as the lung. Emerging evidence suggests similar dysregulation in the placenta may impair function and fetal growth. Ferroptosis, an iron-dependent form of cell death, is driven by the accumulation of labile ferrous iron, catalyzing the peroxidation of polyunsaturated fatty acids in the absence of sufficient iron storage or antioxidant defenses. This pathway has been implicated in SARS-CoV-2-related tissue damage in other organs and may contribute to placental dysfunction during pregnancy. However, the influence of infection timing, symptom severity, and fetal sex on placental iron regulation remains unexamined. We analyzed placental samples from a cohort of SARS-CoV-2-exposed pregnancies in the first (n = 6), second (n = 14), or third trimester (n = 30), classified by symptom severity (asymptomatic n = 23, symptomatic n = 27) and fetal sex, alongside unexposed controls (n = 47). We assessed placental iron deposition, lipid peroxidation, and mRNA and protein expression of ferroptosis markers. Publicly available RNA-sequencing datasets from human placenta tissue, exposed or not to SARS-CoV-2, were analyzed to assess ferroptosis-related gene expression. SARS-CoV-2 infection, particularly in symptomatic cases, was associated with reduced placental weight and birth weight. Asymptomatic cases showed increased placental iron deposition, which correlated with lower birthweight and was accompanied by elevated expression of nuclear receptor coactivator 4, a cytosolic adaptor protein that mediates the selective autophagic degradation of ferritin (ferritinophagy) and iron release. Placentas from symptomatic patients exhibited evidence of altered iron transport and sex-specific down-regulation of antioxidant defenses. Transcriptomic analyses further suggested widespread disruption of ferroptosis pathways in placentas from infected patients. Our findings reveal that SARS-CoV-2 infection alters placental iron homeostasis and is associated with ferroptosis-related changes, with distinct molecular responses based on timing of infection, symptom severity, and fetal sex.
Food Insecurity, Burnout, and Social Isolation Among Resident and Fellow Physicians
Thomas, Larissa R. , Satele, Daniel , Akhtar, Saadia, Ripp, Jonathan , Julian, Katherine A. , Sliwka, Diane, Dyrbye, Liselotte N. , Akhtar, Saadia R. , West, Colin P.

Mayo Clinic

JAMA Network Open | December 17, 2025 | Volume: 8 | Issue: 12 | Pages: e2550044

10.1001/jamanetworkopen.2025.50044 | PMID 41405884 Get It

Importance Little is known about food insecurity (FI) among graduate medical education (GME) trainees or how FI might relate to well-being outcomes in this population. Objectives To assess the prevalence of and factors associated with FI among GME trainees and to investigate the associations of FI with well-being outcomes such as burnout and social isolation in this population. Design, Setting, and Participants In this cross-sectional study, a survey was distributed among 3408 resident and fellow physicians at 4 geographically distinct sites within 2 US academic institutions from May 2 to June 21, 2023. All resident and fellow physicians appointed at both institutions were eligible and were invited by email to participate. Main Outcomes and Measures The primary outcome was prevalence of FI. Measurement instruments included a 2-item FI screening tool, a 2-item measure of burnout, items addressing intent to stay at one’s institution, social isolation, and demographic characteristics. Univariable analysis and multivariable Poisson and linear regression were used to characterize prevalence and factors associated with FI and associations with well-being outcomes and intent to stay at the institution. Results Of those eligible, 1656 residents and fellows participated in the survey (a response rate of 48.6%). Of these respondents, 735 of 1458 (50.4%) who indicated their gender identified as men and 365 of 1402 (26.0%) who indicated their parental status reported having children. Of the 1551 respondents who reported their age, 519 (33.5%) were younger than 30 years, 770 (49.6%) were aged 31 to 35 years, 169 (10.9%) were aged 36 to 40 years, and 53 (3.4%) were older than 40 years. Among 1457 respondents indicating their race and ethnicity, the majority were Asian (310 [21.3%]) or White (654 [44.9%]). The overall prevalence of FI was 13.7%. FI proportions differed across training sites, with higher levels in large metropolitan locations (15.6%, 17.0%, and 21.3% for the 3 sites in large metropolitan areas vs 4.5% for the site in a small metropolitan area; P &amp;lt; .001). There were also differences by postgraduate year (16.9% for postgraduate year 1 vs 10.1% for postgraduate year ≥5; P = .003) and race and ethnicity (22.4% for Black or African American trainees compared with 8.4% for White trainees; P = .04). Those with FI were more likely to experience burnout (adjusted relative risk, 1.37 [95% CI, 1.18-1.60]; P &amp;lt; .001), were less likely to consider remaining at their institution after training (adjusted relative risk, 0.81 [95% CI, 0.68-0.98]; P = .02), and had higher social isolation scores (T-score parameter estimate 2.37 [95% CI, 0.89-3.86]; P = .002). Conclusions and Relevance In this cross-sectional study, nearly 1 in 7 GME trainees screened positive for FI. FI was associated with important well-being outcomes including burnout. These findings suggest that academic medical institutions should pursue systemic solutions to address FI among resident and fellow physicians as a means of supporting their well-being.
Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR
Wudhikarn, Kitsada, Ye, Qiran, Gowda, Lohith , Efebera, Yvonne A. , Boghdadly, Zeinab El , Dandoy, Christopher E. , Akhtar, Othman Salim , Oloyede, Temitope, Perales, Miguel-Angel, Huppler, Anna H, Huppler, Anna R. , Dandoy, Christopher E , Huppler, Anna R , Abid, Muhammad Bilal , Martens, Michael J. , Mirza, Abu‐Sayeef , Devarakonda, Srinivas , Ebens, Christen L. , Hill, Joshua A. , Murthy, Hemant S. , Auletta, Jeffery J.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 716-716

10.1182/blood-2025-716 Get It

Abstract Background: Infections account for over half of the non-relapse deaths among chimeric antigen receptor (CAR) T-cell recipients. Non-relapse mortality estimates are among the highest in patients with relapsed / refractory multiple myeloma (RRMM) receiving B-cell maturation antigen (BCMA)-directed CAR-T cell therapy. The current Center for International Blood and Marrow Transplantation Research (CIBMTR) study analyzed the burden, types, risk factors, and outcomes of infection and its impact on survival in 807 patients with RRMM receiving commercial idecabtagene vicleucel (ide-cel) CAR-T therapy from March 2021 to December 2023. Methods: The primary endpoint was infection density for overall infections and for organism type (bacterial, viral, or fungal) within 100 days post-CAR-T infusion. Infection density was estimated as the number of infections per 100 person days at risk, stratified into two distinct time intervals following CAR-T cell infusion: days 0-30 and days 31-100.Additional endpoints included the cumulative incidence of infections, infection-related mortality (IRM), and overall survival (OS). Multivariable Cox proportional hazards models were employed to identify factors associated with infectious complications within 100 days post-CAR-T cell infusion. Pre-specified risk factors were considered for the multivariable analysis (MVA) models. We further examined the impact of infections within 100 days of CAR-T on OS at any time beyond 100 days following CAR-T infusion. Results: Infections developed in 114 (14.1%) patients within 30 days and 226 (28%) patients within 100 days post-CAR-T infusion, resulting in an overall infection density of 0.49 per 100 patient-days and a 100-day cumulative incidence of 27.2%. Proportions of bacterial, viral, and fungal infections within 30 days of ide-cel infusion were 82 (10.2%), 50 (6.2%), and 5 (0.6%), respectively. Similarly, proportions of bacterial, viral, and fungal infections within 100 days of CAR T-cell infusion were 126 (15.6%), 125 (15.5%), and 8 (1%), respectively, with corresponding infection densities of 0.23, 0.22, and 0.012 per 100 patient-days. The 100-day cumulative incidence of bacterial, viral, and fungal infections were 14.1% (95% CI, 11.8-16.6%), 14.4% (95% CI, 12-16.9%), and 0.9% (95% CI, 0.3-1.6%) respectively. The 100-day IRM was 1.1% (95% CI, 0.5-2%). With a median follow-up of 11.6 months (1.1-26.7), 222 (27.5%) patients died, and infection was the primary cause of death in 17 cases (7.7%). In MVA, Karnofsky performance score ≤80 (p&lt;0.001), infection prior to CAR-T cell infusion requiring with ongoing treatment after d+0 (p&lt;0.001), cytokine release syndrome grade ³2 (p=0.002), and severe immune effector cell-associated neurotoxicity syndrome [ICANS] (grade ≥3) (p&lt;0.001) were associated with an increased infection risk within 100 days post-infusion. Similarly, infection prior to CAR-T infusion requiring with continuing treatment after d+0 (p&lt;0.001 for bacterial and p=0.003 for viral infections) and grade ≥3 ICANS (p&lt;0.001 for bacterial and p=0.015 for viral infections) significantly conferred a heightened risk for bacterial and viral infections within 100 days of CAR-T infusion. Number of infections within 100 days (hazard ratio [HR], 2.36 for ≥2 vs. 0 infections; 95%CI, 1.48-3.77; p&lt;0.001), extramedullary disease or plasma cell leukemia (HR, 1.8; 95%CI, 1.19-2.74; p=0.006), and prior BCMA-directed therapy (HR, 1.57; 95%CI, 1.06-2.33; p=0.025) were independent risk factors for inferior OS beyond day+100 after CAR-T therapy. Intravenous immunoglobulin (IVIG) replacement post-CAR-T therapy conferred a survival advantage (HR, 0.52; 95%CI, 0.38-0.72; p&lt;0.001). Conclusion: In conclusion, study results demonstrate a significant incidence of infections for a prolonged duration (14.1% in the first 30 days and 28% in the first 100 days) in patients with RRMM undergoing ide-cel therapy. Notably, viral infections increased beyond d+30. Multiple infections (≥2 episodes) were associated with inferior OS. Results identify patients at an increased risk for infection and provide insights into risk-adapted interventions to mitigate infections and improve patient outcomes. Furthermore, continued surveillance for infection pre-emption and prevention beyond 3 months post-CAR T therapy may be necessary to reduce infection burden and IRM. Prophylactic strategies such as IVIG replacement could potentially modify infection risk in patients with RRMM receiving ide-cel.
An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis
Kapoor, Prashant , Wang, Shikun , Bal, Susan , Stockerl-Goldstein, Keith , Selvan, S.T., Akhtar, Othman Salim , Lentzsch, Suzanne , Chakraborty, Rajshekhar , D’Souza, Anita , Bhutani, Divaya , Selvan, Sherin, Sanchorawala, Vaishali

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 694-694

10.1182/blood-2025-694 Get It

Abstract Background: The t(11;14) translocation occurs in 50-60% patients with systemic AL amyloidosis. Venetoclax, an oral BCL2 inhibitor, has shown promising efficacy across t(11;14)-positive plasma cell disorders. However, till date, there are no prospective data in patients with previously treated AL amyloidosis, including those with prior exposure to anti-CD38 monoclonal antibodies (mAbs). Methods: We conducted an investigator-initiated phase 1/2 multicenter open-label trial of venetoclax (± dexamethasone) in patients with relapsed/refractory AL amyloidosis. Key inclusion criteria were central-laboratory confirmed t(11;14) by FISH analysis in ≥5% of CD-138-selected cells on bone marrow aspirate, measurable hematologic disease (dFLC≥2 mg/dL and/or M-spike ≥0.5 g/dL), prior exposure to anti-CD38 mAb, and ≥1 prior line of therapy. Key exclusion criteria were NT-proBNP&gt;8500 pg/mL, NYHA class IIIb/IV, and ECOG&gt;2. Phase 1 dose escalation utilized Bayesian Optimal Interval Network (BOIN) design to determine maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) across four levels: DL1 (venetoclax 200mg), DL2 (400mg), DL3 (400mg + dexamethasone 10mg weekly), and DL4 (400mg + dexamethasone 20mg weekly). A maximum of 6 cycles of therapy on the protocol were planned, with dose limiting toxicities (DLTs) being evaluated in cycle 1. The design accommodated 12-15 patients with ~67% probability of selecting the dose closest to the 25% target toxicity rate. Here, we present the results of the Phase 1 portion of the study, which has completed enrollment. Accrual in Phase 2 portion is currently ongoing. Results: Of 16 patients screened, 12 were enrolled and evaluable for safety and efficacy. Screen failures were attributed to second malignancy (n=2), t(11;14) positivity in &lt;5% CD-138-selected cells (n=1), and t(11;14) negativity (n=1). Enrolled patients had a median age of 64 years, with 25% female, and 17% Black representation. At screening, the median percentage of CD-138-selected cells with t(11;14)-positivity on FISH was 65%. All patients had prior anti-CD38 mAb-exposure by protocol design, with 11/12 patients also exposed to bortezomib. The median number of prior lines of therapy was 1 (range, 1-5). Disease markers at treatment initiation included median dFLC of 14.35 mg/dL (range, 2.13-186.28), median NT-proBNP of 712.5 pg/mL (range, 54-8831), and the median serum creatinine of 0.99 mg/dL (range, 0.69-3.01). Regarding safety, there were no DLTs encountered during the specified timeframe. One patient each received DLs 1, 2, and 3, with all remaining patients receiving DL 4 (400mg + dexamethasone 20mg weekly), which is the RP2D in this trial. There was only one patient that developed grade 3 infection (lung infection; COVID-19). No tumor-lysis syndrome, grade 3 or higher cytopenia, or treatment-emergent deaths occurred. Hematologic overall response (PR or better) was achieved in 11/12 patients (91.7%), with 9/12 (75%) attaining ≥VGPR [4/12 (33.3%) heme-CR, with the remaining being VGPR]. The median time from treatment initiation to best response was 29 days. Among 7 patients that were evaluable for cardiac response, one underwent heart transplant after 3 cycles of study treatment (while in heme-CR), hence was no longer evaluable for cardiac organ response. Of the remaining 6 patients, 2 have achieved cardiac response till date. Renal organ response was observed in 4/7 evaluable patients. At a median follow-up of 8.8 months, 4 out of 12 patients have completed 6 treatment cycles, with 2 receiving ongoing therapy. Six patients discontinued treatment early due to hematologic progression (n=1), suboptimal hematologic response (n=2), patient preference (n=2), and heart transplant (n=1). Patient-reported outcomes (assessed by PROMIS-29) showed no significant changes in Physical Functioning and Fatigue domains among 5 patients with paired baseline and end-of-treatment assessments. Updated follow-up data will be presented at the meeting. Conclusions: To our knowledge, this represents the first prospective evaluation of venetoclax-dexamethasone in relapsed/refractory t(11;14) AL amyloidosis. The combination demonstrated substantial hematologic efficacy (75% ≥VGPR rate) and a favorable safety profile without dose-limiting toxicities. Our results support investigation of venetoclax-based combinations in the frontline treatment of newly diagnosed t(11;14) AL amyloidosis.
SURP-02. Re-ETV versus Ventriculoperitoneal Shunting in Failed ETV in Pediatric Patients with Hydrocephalus: A Systematic Review
Ahmed, Ikhlas , Choudry, Usama Khalid , Basit, Abdul , Nasir, Roua , Noor, Ahmed , Pasha, Muhammad Saad, Akhunzada, Naveed Zaman, Arif, Aabiya , Godfrey, Oswin, Nathani, Karim Rizwan , Khan, Saad Akhtar , Haque, Minza, Noor, Ahmed

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v418-v419

10.1093/neuonc/noaf201.1657 Get It

Abstract INTRODUCTION Hydrocephalus in pediatric patients is commonly treated with endoscopic third ventriculostomy (ETV) or ventriculoperitoneal shunting (VPS). When primary ETV fails, clinicians must decide between repeat ETV (Re-ETV) and VPS placement. However, the optimal secondary intervention remains debated. Objective: To compare the efficacy and outcomes of Re-ETV versus VPS placement following failed primary ETV in pediatric hydrocephalus. METHODS We conducted a systematic review following PRISMA guidelines. Searches of PubMed, Embase, and the Cochrane Library identified English-language studies (2001–2023) reporting on Re-ETV or VPS after failed primary ETV in patients aged 0–18 years. Comparative studies, including randomized controlled trials, cohort studies, and prospective designs were eligible. Two independent reviewers screened titles, abstracts, and full texts; extracted data on sample size, intervention rates, failure rates, and complications; and assessed study quality using RoB 2.0 and CASP tools. Pooled descriptive statistics and odds ratios (OR) were calculated for secondary intervention failure. RESULTS Nine studies (n = 663) met inclusion criteria. Re-ETV was performed in 220 patients (33.2%) and VPS in 443 (66.8%). Primary ETV failure rates ranged from 16.6% to 60.9% (mean 40.6%). Re-ETV exhibited a pooled failure rate of 74.98%, whereas VPS failure was 22.26% (OR 4.86; 95% CI 3.21–7.38; p &lt; 0.05). Hemorrhagic etiology during primary ETV significantly favored VPS over Re-ETV (p &lt; 0.05). Time to secondary failure averaged 15.8 ± 21.7 months, with broad inter-study variability. CONCLUSION VPS placement demonstrates a substantially lower failure rate than Re-ETV as a secondary intervention after primary ETV failure in pediatric hydrocephalus. Nevertheless, variability in patient age, etiology, and follow-up underscores the necessity of individualized decision-making. Prospective trials with standardized outcome measures are warranted to refine secondary treatment guidelines.